glp 1 age limit Are there restrictions on GLP-1s? BMI for GLP-1: what body

Conclusions In this cohort study, the GLP-1 receptor agonist-SGLT-2 inhibitor combination was associated with a lower risk of major adverse cardiovascular events and serious renal events compared with either drug class alone

Cardiovascular Outcomes with Orally Administered Semaglutide PIONEER 6 (NCT02692716) was an event-driven CVOT designed to confirm that treatment with orally administered semaglutide does not result in an unacceptable increase in CV risk compared with placebo

GLP-1 medicines can reduce appetite, but your body still needs enough energy and nutrients to function well

Gong S, Chen J, Zheng X, Lu X, Chen M, Li J, et al

Any consideration of investigational approaches should occur only within the context of clinical trials or with explicit acknowledgment of the limited evidence base and careful risk-benefit assessment tailored to your specific clinical circumstances